Caution in the interpretation of safety and efficacy differences in clinical trials comparing aminosalicylates for ulcerative colitis-Reference-Cited by-同舟云学术

Caution in the interpretation of safety and efficacy differences in clinical trials comparing aminosalicylates for ulcerative colitis

Published:2003-01 Issue:1 Volume:98 Page:215-216
ISSN:0002-9270
Container-title:The American Journal of Gastroenterology
language:en
Short-container-title:Am J Gastroenterology

Author:

Hanauer Stephen B.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Gastroenterology,Hepatology

Reference8 articles.

1. A randomized, double blind, dose-response comparison of balsalazide (6.75 g), balsalazide (2.25 g), and mesalamine (2.4 g) in the treatment of active, mild-to-moderate ulcerative colitis1

2. Balsalazide is superior to mesalamine in the time to improvement of signs and symptoms of acute ulcerative colitis

3. 3. A phase III randomized, placebo-controlled, double-blind, dose response comparison of Colazide 4.5 g and 6.75 g daily vs placebo in patients with active mild to moderate ulcerative colitis . Colazide (balsalazide disodium) UK Monograph.

4. Balsalazide is more effective and better tolerated than mesalamine in the treatment of acute ulcerative colitis

5. Equimolar doses of balsalazide and mesalamine: are we comparing apples and oranges?

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Colon, Rectum, and Anus;Surgery;2008

2. Indications for 5-aminosalicylate in inflammatory bowel disease: Is the body of evidence complete;World Journal of Gastroenterology;2006

3. Update in Medical Therapy of Ulcerative Colitis;Journal of Clinical Gastroenterology;2005-08

4. Dose escalation of 5ASA: does it work?;Digestive and Liver Disease;2005-02

5. Mesalamine delivery systems: do they really make much difference?;Advanced Drug Delivery Reviews;2005-01